首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Outcome of radical local treatment of non-small cell lung cancer patients with synchronous oligometastases
【24h】

Outcome of radical local treatment of non-small cell lung cancer patients with synchronous oligometastases

机译:非小细胞肺癌同步寡粒子患者的局部局部治疗结果

获取原文
获取原文并翻译 | 示例
           

摘要

Highlights " 91 patients treated radical with synchronous oligometastatic NSCLC. " Favorable OS and PFS for this patient group. " Radical local treatment strategies should be part of future prospective studies. Abstract Objectives Patients with stage IV non-small cell lung cancer (NSCLC) are considered incurable and are mainly treated with palliative intent. This patient group has a poor overall survival (OS) and progression free survival (PFS). The purpose of this study was to investigate PFS and OS of NSCLC patients diagnosed with synchronous oligometastatic disease who underwent radical treatment of both intrathoracic disease and metastases. Materials and methods Patients with NSCLC and oligometastatic disease at diagnosis, who were treated with radical intent between 2008 and 2016, were included in this observational study. Treatment consisted of systemic treatment and radical radiotherapy or resection of the intrathoracic disease. Treatment of the metastases consisted of radical or stereotactic radiotherapy, surgical resection or radiofrequency ablation. Results and conclusions Ninety-one patients (52% men, mean age 60 years) in good performance status were included. Thirty-eight patients (42%) died during follow-up (median follow-up 35 months). The cause of dead was lung cancer in all patients, except one. Sixty-three (69%) patients developed recurrent disease. Eleven recurrences (17%) occurred within the irradiated area. For the whole group, the median PFS was 14 months (range 289, 95%CI 1216) and the median OS was 32 months (range 389, 95%CI 2539). The 1- and 2-year OS rates were 85% and 58% and the 1- and 2-year PFS rates were 55% and 27%, respectively. Radical local treatment of a selected group of NSCLC patients with good performance status presenting with synchronous oligometastatic disease resulted in favorable long-term PFS and OS.
机译:亮点“91例患者用同步寡芯片间NSCLC处理的。”这种患者组的有利OS和PFS。 “激进的本地治疗策略应该是未来前瞻性研究的一部分。摘要目标阶段非小细胞肺癌(NSCLC)的患者被认为是可现死的,主要用姑息性意图治疗。该患者组总生存率差(OS)差和进展免费生存(PFS)。本研究的目的是探讨诊断出患有同步寡粒子疾病的NSCLC患者的PFS和OS,患有胸腔内疾病和转移的自由基治疗。诊断中的NSCLC和寡粒度疾病的材料和方法患者,世卫组织在2008年至2016年间受到激进的意图,被列入了这项观察研究。治疗组成,由全身治疗和自由基放射治疗或切除胸内疾病。转移组成,由基团或立体定向放射治疗,手术切除或射频消融组成。结果和结论九十一位患者(52%)包括良好的绩效状况,平均60岁60岁。三十八名患者(42%)在随访期间死亡(中位随访35个月)。死亡的原因是所有患者的肺癌,除了一个。六十三(69%)患者发育经常性疾病。在照射区域内发生11次复发(17%)。对于整个组,中位数PFS为14个月(289,95%CI 1216),中位数OS为32个月(范围389,95%CI 2539)。 1和2年的OS率为85%,58%,而且,1年和2年的PFS率分别为55%和27%。采用同步寡粒子疾病呈现出良好的性能状态的所选NMSCLC患者的自由基局部治疗导致有利的长期PFS和OS。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号